Healthcare
Modular Medical Announces Contract with National U.S. Pharmacy Benefit Manager, Expanding Access to Pivot Tubeless Patch Pump
Sep 4 · 12:00Newswire.com
7,171 press releases indexed under healthcare.
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO ® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline.
First-ever Flying Eye Hospital training project in Macau, supported by Alcon and OMEGA, highlights two decades of local support advancing eye health in China and around the world. MACAU, Sept. 4, 2026 /PRNewswire/ -- Global eye care nonprofit Orbis International is celebrating 20 years of...
Friday 4 September, 2026 New research could transform the way scientists study leukaemia while reducing the need for animals in research A major new research grant aiming to improve our understanding of leukaemia while reducing the use of animals in science has been announced today to mark World Leukaemia Day (4 September). Funded by The Humane Research Trust, with support from Naturewatch Foundation, the £450,000 grant will enable Dr Minerva Bosch-Fortea at Barts Cancer Institute to develop a pioneering 100% animal-free model of the leukaemia bone marrow environment. Leukaemia affects thousands of people across the UK every year, with around 9,900 new cases diagnosed annually - equivalent to around 27 people every day. Despite advances in treatment, treatment resistance remains a major ch
Innovative healthcare model emphasizes a more personalized, convenient approach to pediatric care ROCKVILLE CENTRE, N.Y., Sept. 4, 2026 /PRNewswire/ -- Concierge Choice Physicians (CCP), the nation's leading full-service concierge medical service provider, announced today that two...
The World Health Organization (WHO) has validated Bhutan's elimination of dog-transmitted rabies as a public health problem in the country. Bhutan is the first country in the WHO South-East Asia Region to achieve this success. - - Rabies is a viral disease that is almost always fatal once clinical symptoms appear. However, rabies deaths are preventable. On one hand, vaccinating dogs curbs the disease at its source; on the other, prompt use of post exposure prophylaxis (PEP) stops the virus... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=360023
Arup has helped deliver the country's first purpose-built National Rehabilitation Centre (NRC) for NHS patients. Run and staffed by Nottingham University Hospitals NHS Trust (NUH), the new facility will provide specialist rehabilitation care for people recovering from life changing injuries and illnesses. - - Located near Loughborough, UK, the £105 million, 70 bed centre is part of the Government's New Hospital Programme which aims to renew the NHS estate while improving patient safety and... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=360019
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentations at the following investor conferences:
(PR-inside.com) Internal data from more than 200 professional AI citation audits documents a widening gap between brands working under a documented five-signal AEO methodology and brands working with agencies that claim AEO without a documented standard, identifying specific performance differences across legal, medical, financial, and technology sectors. AMHERST, NY / ACCESS Newswire / September 4, 2026 / Trustpoint Xposure, the first AEO-certified PR agency in the United States , today released its 2026 State of AEO Report, a comprehensive internal analysis documenting the performance gap between certified and uncertified AEO methodology across legal, medical, financial, and technology professional categories. The report draws on ..
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 4, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ..
FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development ALAMEDA, Calif. and TAIPEI, Sept. 4, 2026 /PRNewswire/ -- Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell...